Alzamend Neuro

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Alzamend Neuro is dedicated to improving the lives of patients affected by neurological diseases, and to providing hope to individuals and families affected by Alzheimer's disease.

Our vision is to be the world’s leader in the development and delivery of breakthrough therapies that improve the quality of life for individuals and families affected by Alzheimer's disease.

Alzamend Neuro has received numerous awards over the years, including a Technology and Practice Award from the Alzheimer’s Association in 2009, an Innovator of the Year award from BioMichigan in 2011, and a Breakthrough Award from the National Institute of Health in 2013.